Contraception By Women Of Reproductive Potential With A Body Mass Index (Bmi) < 30 Kg/m2

Contraceptive, Progestin-only contraception 

Agile Therapeutics is a forward-looking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. The Company's initial product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on Company's proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. The Company may occasionally disseminate material, nonpublic information on the Company's website.

Drug & Indication	Stage & Event	Catalyst Date
Twirla (levonorgestrel and ethinyl estradiol) transdermal system Details Contraception By Women Of Reproductive Potential With A Body Mass Index (Bmi) < 30 Kg/m2	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AG890 Details Contraceptive, Progestin-only contraception	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.

Drug Pipeline

Powered by